Search

Your search keyword '"Ritter, Gerd"' showing total 383 results
Start Over Author "Ritter, Gerd" Publication Type Academic Journals
383 results on '"Ritter, Gerd"'

2. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, Bernard A, Schendel, Dolores J, Butterfield, Lisa H, Aamdal, Steinar, Allison, James P, Ascierto, Paolo, Atkins, Michael B, Bartunkova, Jirina, Bergmann, Lothar, Berinstein, Neil, Bonorino, Cristina C, Borden, Ernest, Bramson, Jonathan L, Britten, Cedrik M, Cao, Xuetao, Carson, William E, Chang, Alfred E, Characiejus, Dainius, Choudhury, A Raja, Coukos, George, de Gruijl, Tanja, Dillman, Robert O, Dolstra, Harry, Dranoff, Glenn, Durrant, Lindy G, Finke, James H, Galon, Jerome, Gollob, Jared A, Gouttefangeas, Cécile, Grizzi, Fabio, Guida, Michele, Håkansson, Leif, Hege, Kristen, Herberman, Ronald B, Hodi, F Stephen, Hoos, Axel, Huber, Christoph, Hwu, Patrick, Imai, Kohzoh, Jaffee, Elizabeth M, Janetzki, Sylvia, June, Carl H, Kalinski, Pawel, Kaufman, Howard L, Kawakami, Koji, Kawakami, Yutaka, Keilholtz, Ulrich, Khleif, Samir N, Kiessling, Rolf, Kotlan, Beatrix, Kroemer, Guido, Lapointe, Rejean, Levitsky, Hyam I, Lotze, Michael T, Maccalli, Cristina, Maio, Michele, Marschner, Jens-Peter, Mastrangelo, Michael J, Masucci, Giuseppe, Melero, Ignacio, Melief, Cornelius, Murphy, William J, Nelson, Brad, Nicolini, Andrea, Nishimura, Michael I, Odunsi, Kunle, Ohashi, Pamela S, O'Donnell-Tormey, Jill, Old, Lloyd J, Ottensmeier, Christian, Papamichail, Michael, Parmiani, Giorgio, Pawelec, Graham, Proietti, Enrico, Qin, Shukui, Rees, Robert, Ribas, Antoni, Ridolfi, Ruggero, Ritter, Gerd, Rivoltini, Licia, Romero, Pedro J, Salem, Mohamed L, Scheper, Rik J, Seliger, Barbara, Sharma, Padmanee, Shiku, Hiroshi, Singh-Jasuja, Harpreet, Song, Wenru, Straten, Per, Tahara, Hideaki, Tian, Zhigang, van Der Burg, Sjoerd H, von Hoegen, Paul, Wang, Ena, Welters, Marij JP, Winter, Hauke, Withington, Tara, Wolchok, Jedd D, Xiao, Weihua, and Zitvogel, Laurence

Abstract

Abstract Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

Published
2011

5. Recombinant NY-ESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans

Author

Davis, Ian D., Chen, Weisan, Jackson, Heather, Parente, Phillip, Shackleton, Mark, Hopkins, Wendie, Chen, Qiyuan, Dimopoulos, Nektaria, Luke, Tina, Murphy, Roger, Scott, Andrew M., Maraskovsky, Eugene, McArthur, Grant, MacGregor, Duncan, Sturrock, Sue, Tai, Tsin Yee, Green, Simon, Cuthbertson, Andrew, Maher, Darryl, Miloradovic, Lena, Mitchell, Susan V., Ritter, Gerd, Jungbluth, Achim A., Chen, Yao-Tseng, Gnjatic, Sacha, Hoffman, Eric W., Old, Lloyd J., and Cebon, Jonathan S.

Published
2004

16. PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

Author

Zanzonico, Pat, Carrasquillo, Jorge A., Pandit-Taskar, Neeta, O’Donoghue, Joseph A., Humm, John L., Smith-Jones, Peter, Ruan, Shutian, Divgi, Chaitanya, Scott, Andrew M., Kemeny, Nancy E., Fong, Yuman, Wong, Douglas, Scheinberg, David, Ritter, Gerd, Jungbluth, Achem, Old, Lloyd J., and Larson, Steven M.

Published
2015
Full Text
View/download PDF

17. Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1

Author

dos Santos, Luara Isabela, Galvão-Filho, Bruno, de Faria, Paula Cristina, Junqueira, Caroline, Dutra, Miriam Santos, Teixeira, Santuza Maria Ribeiro, Rodrigues, Maurício Martins, Ritter, Gerd, Bannard, Oliver, Fearon, Douglas Thomas, Antonelli, Lis Ribeiro, and Gazzinelli, Ricardo Tostes

Published
2015
Full Text
View/download PDF

19. Trypanosoma cruzi as an effective cancer antigen delivery vector

Author

Junqueira, Caroline, Santos, Luara I., Galvão-Filho, Bruno, Teixeira, Santuza M., Rodrigues, Flávia G., DaRocha, Wanderson D., Chiari, Egler, Jungbluth, Achim A., Ritter, Gerd, Gnjatic, Sacha, Old, Lloyd J., and Gazzinelli, Ricardo T.

Published
2011

20. Integrated NY-ESO-1 antibody and CD8⁺ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Author

Yuan, Jianda, Adamow, Matthew, Ginsberg, Brian A., Rasalan, Teresa S., Ritter, Erika, Gallardo, Humilidad F., Xu, Yinyan, Pogoriler, Evelina, Terzulli, Stephanie L., Kuk, Deborah, Panageas, Katherine S., Ritter, Gerd, Sznol, Mario, Halaban, Ruth, Jungbluth, Achim A., Allison, James P., Old, Lloyd J., Wolchok, Jedd D., and Gnjatic, Sacha

Published
2011

21. Seromic profiling of ovarian and pancreatic cancer

Author

Gnjatic, Sacha, Ritter, Erika, Büchler, Markus W., Giese, Nathalia A., Brors, Benedikt, Frei, Claudia, Murray, Anne, Halama, Niels, Zörnig, Inka, Chen, Yao-Tseng, Andrews, Christopher, Ritter, Gerd, Old, Lloyd J., Odunsi, Kunle, and Jäger, Dirk

Published
2010
Full Text
View/download PDF

22. Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR

Author

Garrett, Thomas P. J., Burgess, Antony W., Gan, Hui K., Luwor, Rod B., Cartwright, Glenn, Walker, Francesca, Orchard, Suzanne G., Clayton, Andrew H. A., Nice, Edouard C., Rothacker, Julie, Catimel, Bruno, Cavenee, Webster K., Old, Lloyd J., Stockert, Elisabeth, Ritter, Gerd, Adams, Timothy E., Hoyne, Peter A., Wittrup, Dane, Chao, Ginger, Cochran, Jennifer R., Luo, Cindy, Lou, Mezhen, Huyton, Trevor, Xu, Yibin, Fairlie, W. Douglas, Yao, Shenggen, Scott, Andrew M., Johns, Terrance G., and Adams, Jerry M.

Published
2009
Full Text
View/download PDF

23. CTLA-4 Blockade Enhances Polyfunctional NY-ESO-1 Specific T Cell Responses in Metastatic Melanoma Patients with Clinical Benefit

Author

Yuan, Jianda, Gnjatic, Sacha, Li, Hao, Powel, Sarah, Gallardo, Humilidad F., Ritter, Erika, Ku, Geoffrey Y., Jungbluth, Achim A., Segal, Neil H., Rasalan, Teresa S., Manukian, Gregor, Xu, Yinyan, Roman, Ruth-Ann, Terzulli, Stephanie L., Heywood, Melanie, Pogoriler, Evelina, Ritter, Gerd, Old, Lloyd J., Allison, James P., and Wolchok, Jedd D.

Published
2008
Full Text
View/download PDF

27. Vaccination with NY-ESO-1 Protein and CpG in Montanide Induces Integrated Antibody/Th1 Responses and CD8 T Cells through Cross-Priming

Author

Valmori, Danila, Souleimanian, Naira E., Tosello, Valeria, Bhardwaj, Nina, Adams, Sylvia, O'Neill, David, Pavlick, Anna, Escalon, Juliet B., Cruz, Crystal M., Angiulli, Angelica, Angiulli, Francesca, Mears, Gregory, Vogel, Susan M., Pan, Linda, Jungbluth, Achim A., Hoffmann, Eric W., Venhaus, Ralph, Ritter, Gerd, Old, Lloyd J., and Ayyoub, Maha

Published
2007
Full Text
View/download PDF

28. A Phase I Clinical Trial with Monoclonal Antibody ch806 Targeting Transitional State and Mutant Epidermal Growth Factor Receptors

Author

Scott, Andrew M., Lee, Fook-Thean, Tebbutt, Niall, Herbertson, Rebecca, Gill, Sanjeev S., Liu, Zhanqi, Skrinos, Effie, Murone, Carmel, Saunder, Timothy H., Chappell, Bridget, Papenfuss, Anthony T., Poon, Aurora M. T., Hopkins, Wendie, Smyth, Fiona E., MacGregor, Duncan, Cher, Lawrence M., Jungbluth, Achim A., Ritter, Gerd, Brechbiel, Martin W., Murphy, Roger, Burgess, Antony W., Hoffman, Eric W., Johns, Terrance G., and Old, Lloyd J.

Published
2007
Full Text
View/download PDF

35. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Author

Schmitt, Michael, Schmitt, Anita, Rojewski, Markus T., Chen, Jinfei, Giannopoulos, Krzysztof, Fei, Fei, Yu, Yingzhe, Götz, Marlies, Heyduk, Marta, Ritter, Gerd, Speiser, Daniel E., Gnjatic, Sacha, Guillaume, Philippe, Ringhoffer, Mark, Schlenk, Richard F., Liebisch, Peter, Bunjes, Donald, Shiku, Hiroshi, Dohner, Hartmut, and Greiner, Jochen

Published
2008
Full Text
View/download PDF

37. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer

Author

Laban, Simon, Atanackovic, Djordje, Luetkens, Tim, Knecht, Rainald, Busch, Chia-Jung, Freytag, Marcus, Spagnoli, Giulio, Ritter, Gerd, Hoffmann, Thomas K., Knuth, Alexander, Sauter, Guido, Wilczak, Waldemar, Blessmann, Marco, Borgmann, Kerstin, Muenscher, Adrian, and Clauditz, Till S.

Published
2014
Full Text
View/download PDF

43. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation

Author

Atanackovic, Djordje, Arfsten, Julia, Cao, Yanran, Gnjatic, Sacha, Schnieders, Frank, Bartels, Katrin, Schilling, Georgia, Faltz, Christiane, Wolschke, Christine, Dierlamm, Judith, Ritter, Gerd, Eiermann, Thomas, Hossfeld, Dieter Kurt, Zander, Axel R., Jungbluth, Achim A., Old, Lloyd J., Bokemeyer, Carsten, and Kröger, Nicolaus

Published
2007
Full Text
View/download PDF

45. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines

Author

Nishikawa, Hiroyoshi, Sato, Eiichi, Briones, Gabriel, Chen, Li-Mei, Matsuo, Mitsutoshi, Nagata, Yasuhiro, Ritter, Gerd, Jager, Elke, Nomura, Hideki, Kondo, Shigeto, Tawara, Isao, Kato, Takuma, Shiku, Hiroshi, Old, Lloyd J., Galan, Jorge E., and Gnjatic, Sacha

Subjects
Cancer vaccines -- Research, Cancer -- Prevention, Cancer -- Research, Medical research, Medicine, Experimental
Abstract

Bacterial vectors may offer many advantages over other antigen delivery systems for cancer vaccines. We engineered a Salmonella typhimurium vaccine strain to deliver the NY-ESO-1 tumor antigen (S. typhimurium-NY-ESO-1) through [...]

Published
2006

46. Intraepithelial CD[8.sup.+] tumor-infiltrating lymphocytes and a high CD[8.sup.+]/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

Author

Sato, Eiichi, Olson, Sara H., Ahn, Jiyoung, Bundy, Brian, Nishikawa, Hiroyoshi, Qian, Feng, Jungbluth, Achim A., Frosina, Denise, Gnjatic, Sacha, Ambrosone, Christine, Kepner, James, Odunsi, Tosin, Ritter, Gerd, Lele, Shashikant, Chen, Yao-Tseng, Ohtani, Haruo, Old, Lloyd J., and Odunsi, Kunle

Subjects
Ovarian cancer -- Prognosis, T cells -- Research, Tumor-infiltrating lymphocytes -- Research, Science and technology
Abstract

In a recent report, [Zhang et al. (2003) N. Engl. J. Med, 348, 203-213], the presence of CD[3.sup.+] tumor-infiltrating lymphocytes (TILs) was found to correlate with improved survival in epithelial ovarian cancer. We performed immunohistochemical analysis for TILs and cancer testis antigens in 117 cases of epithelial ovarian cancer. The interrelationship between subpopulations of TILs and expression of cancer testis antigens was investigated, as well as between TILs and overall survival. The median follow-up of the patients was 31 months. Patients with higher frequencies of intraepithelial CD[8.sup.+] T cells demonstrated improved survival compared with patients with lower frequencies [median = 55 versus 26 months; hazard ratio = 0.33; confidence interval (C.I.) = 0.18-0.60; P = 0.0003]. No association was found for CD[3.sup.+] TILs or other subtypes of intraepithelial or stromal TILs. However, the subgroups with high versus low intraepithelial CD[8.sup.+]/CD[4.sup.+] TIL ratios had median survival of 74 and 25 months, respectively (hazard ratio = 0.30; C.I. = 0.16-0.55; P = 0.0001). These results indicate that CD[4.sup.+] TILs influence the beneficial effects of CD[8.sup.+] TIL. This unfavorable effect of CD[4.sup.+] T cells on prognosis was found to be due to [CD25.sup.+] forkhead box P3 [(FOXP3).sup.+] regulatory T cells (Treg; suppressor T cells), as indicated by survival of patients with high versus low CD[8.sup.+]/Treg ratios (median = 58 versus 23 months; hazard ratio = 0.31; C.I. = 0.17-0.58; P = 0.0002). The favorable prognostic effect of intraepithelial CD[8.sup.+] TILs did not correlate with concurrent expression of NY-ESO-1 or MAGE antigens. We conclude that intraepithelial CD[8.sup.+] TILs and a high CD[8.sup.+]/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer. cancer testis antigen | CD[8.sup.+] T cell

Published
2005

47. IFN-[gamma] enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation

Author

Matsuo, Mitsutoshi, Nagata, Yasuhiro, Sato, Eiichi, Atanackovic, Djordje, Valmori, Danila, Chen, Yao-Tseng, Ritter, Gerd, Mellman, Ira, Old, Lloyd J., and Gnjatic, Sacha

Subjects
Transforming growth factors -- Research, Dendritic cells -- Research, Science and technology
Abstract

We compared monocyte-derived dendritic cells and transforming growth factor-[beta]1-induced Langerhans-like cells (LCs) for their capacity to cross-present exogenous NY-ESO-1 protein/antibody immune complexes to an NY-ESO-l-specific CD8+ T cell clone. In contrast to dendritic cells, LCs were not able to cross-present NY-ESO-1 to the T cell clone constitutively but did so after treatment with IFN-[gamma]. Remarkably. this IFN-[gamma]-inducible characteristic was due neither to enhanced antigen uptake nor to facilitated antigen processing in LCs. Rather, IFN-[gamma] acted at least in part by potentiating the maturation of otherwise refractory LCs, enabling in turn exogenous antigen to reach the processing machinery. This model of conditional cross-presentation establishes an original level of action for IFN-[gamma] as an effective immune modulator and supports the use of IFN-[gamma] in protein vaccination strategies targeting LCs.

Published
2004

49. Survey of naturally occurring [CD4.sup.+] T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

Author

Gnjatic, Sacha, Atanackovic, Djordje, Jager, Elke, Matsuo, Mitsutoshi, Selvakumar, Annamalai, Altorki, Nasser K., Maki, Robert G., Dupont, Bo, Ritter, Gerd, Chen, Yao-Tseng, Knuth, Alexander, and Old, Lloyd J.

Subjects
Tumor antigens -- Physiological aspects, T cells -- Research, Science and technology, National Academy of Sciences -- Research
Abstract

NY-ESO-1 is one of the most immunogenic proteins described in human cancers, based on its capacity to elicit simultaneous antibody and [CD8.sup.+] T cell responses in vivo. Although HLA class II restricted epitopes from NY-ESO-1 have been identified, no broad survey has yet established the status of natural [CD4.sup.+] T cell responses in cancer patients in relation to [CD8.sup.+] and antibody responses. We used a recently developed general strategy for monitoring [CD4.sup.+] responses that overcomes the need for prior knowledge of epitope or HLA restriction to analyze a series of 31 cancer patients and healthy donors for the presence of [CD4.sup.+] T cells to NY-ESO-1, and related this response to NY-ESO-1 expression in tumor cells and serum antibodies to NY-ESO-1. None of the 18 patients that tested seronegative for NY-ESO-1 had detectable [CD4.sup.+] T cell responses. On the contrary, 11 of 13 cancer patients with serum antibodies to NY-ESO-1 had polyclonal [CD4.sup.+] T cell responses directed against various known and previously undescribed NY-ESO-1 epitopes. NY-ESO-1 peptide 80-109 was the most immunogenic, with 10 of 11 patients responding to this peptide. We show here that 12-mer determinants from NY-ESO-1 eliciting a [CD4.sup.+] T cell response were peptide 87-98 with promiscuous HLA class II presentation, peptide 108-119 restricted by HLA-DP4, and peptides 121-132 and 145-156, both shorter epitopes from previously described HLA-DR4 peptides, also presented by HLA-DR7. This study represents the next step in compiling a comprehensive picture of the adaptive immune response to NY-ESO-1, and provides a general strategy for analyzing the [CD4.sup.+] T cell response to other tumor antigens eliciting a humoral immune response.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results